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 Making Research
 a Requirement of Treatment
 Why We Should Sometimes Let Doctors Pressure Patients
 to Participate in Research
 by DAVID ORENTLICHER
 When a patient could be offered one of multiple established treatments, doctors should be able to
 offer treatment only if the patient agrees to participate in research aimed at determining which of the
 treatments is most effective. Making treatment conditional on research participation will help researchers
 complete badly needed studies.
 In recent years, a number of events have raised
 concerns about the adequacy of safeguards to
 protect people who volunteer for medical re-
 search. Individuals without a serious illness, like
 Jesse Gelsinger and Ellen Roche, have died unex-
 pectedly while participating in clinical trials.' The
 federal Office for Human Research Protections tem-
 porarily halted studies at several major academic
 centers for their failure to observe research guide-
 lines.2 Overseas trials of HIV-therapy during preg-
 nancy have been criticized for including a placebo
 control arm.3 For some studies, we must worry
 whether research subjects are placed at too great a
 risk by physicians seeking to advance medical
 knowledge.
 At the same time, we must also question whether
 research safeguards are sometimes overly protective
 of people who might enter clinical trials. Progress in
 treating trauma patients, for example, was hampered
 for many years by the requirements of informed
 consent-seriously injured patients often lack the
 decision-making capacity necessary to agree to en-
 rollment in a research trial, and family members may
 not be available to consent to the trial on their be-
 half. These difficulties in enrolling patients slowed
 the development of promising therapies-including
 more effective methods for cardiac resuscitation and
 substitutes for blood to transfuse patients who have
 suffered major blood loss.4 To address this problem,
 federal guidelines for informed consent were modi-
 fied in 1996 to permit valuable research in the emer-
 gency setting.5
 This article argues that just as there was a need to
 relax the requirements of informed consent for trau-
 ma research, there is a need to relax the precautions
 taken to ensure voluntary participation of subjects in
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 another kind of research trial-stud-
 ies involving the comparison of two
 or more established therapies to see
 whether one is superior to the alter-
 native(s). For many medical prob-
 lems, physicians can choose among
 multiple therapeutic options, and the
 choice is typically based more on
 hunch than on data. Patients would
 benefit greatly from studies that cari-
 fy the relative benefits and risks of
 different options for their illnesses.
 However, these studies can be de-
 layed-and medical progress imped-
 ed-by difficulties in securing the
 participation of enough individuals.6
 In the AFFIRM study comparing the
 two leading therapies for chronic atri-
 al fibrillation, for example, only fifty-
 five percent of patients invited to en-
 roll in the study chose to do so.7 In a
 study of alternative therapies for some
 chronic lung diseases (including asth-
 ma and emphysema), more than half
 of the patients invited to participate
 in the study declined the invitation,
 with total recruitment taking twice as
 long as expected (sixteen months in-
 stead of eight months).8
 Patients decline invitations to en-
 roll for a number of reasons. Some
 people are uncomfortable with the
 idea of being part of a testing process,
 or with the possibility that which
 treatment they will receive will be de-
 cided randomly.9 Many of these pa-
 tients are concerned that the physi-
 cians are more interested in the re-
 search study than in the patient's
 care.'0 Patients also cite concerns
 about the burden of extra tests and
 appointments and the uncertainty of
 the consequences for their health
 from participation."
 Researchers and trial sponsors
 have employed a number of ap-
 proaches to address the difficulties in
 recruiting patients for clinical trials.
 Some have employed more intensive
 recruitment practices, including no-
 tices on radio and television.12 Others
 have taken their trials overseas, where
 recruitment is often easier.13 But these
 alternatives are either insufficiently
 effectivel4 or raise their own ethical
 concerns.15
 This article argues on behalf of an-
 other way to increase patient enroll-
 ment in clinical trials: It should be
 permissible for a physician to condi-
 tion a patient's access to treatment on
 the patient's willingness to enter a
 clinical trial when the trial compares
 two or more accepted therapies to
 find out whether they are equivalent
 or whether one is better than the oth-
 ers. That is, the physician should be
 able to offer treatment to the patient
 only in the setting of the cinical trial.
 Patients who declined to participate
 in the study would have to receive
 care from another physician.
 Concerns about ensuring that pa-
 tients participate in research truly vol-
 untarily discourage or prevent physi-
 cians from employing such a mea-
 sure. Conditioning treatment on a
 patient's willingness to enroll in a trial
 is thought to constitute unacceptable
 coercion. But in fact, linking treat-
 ment to participation in research
 could be a valuable and ethically
 sound way to increase patient partici-
 pation, as long as the clinical trial in-
 volves a comparison of alternative, es-
 tablished therapies.
 Hypothetical Case Study
 As an illustration of the concern
 with current standards for in-
 formed consent in research, consider
 the following hypothetical case study,
 which is based on an important, fed-
 erally funded cinical trial.
 The cinical trial was the Atrial
 Fibrillation Follow-up Investigation
 of Rhythm Management (AFFIRM)
 trial.16 Sponsored by the National
 Heart, Lung, and Blood Institute,
 AFFIRM compared two established
 treatment strategies for persistent or
 recurrent atrial fibrillation to see if
 one offered either better outcomes or
less adverse effects.17 In one strategy,
 physicians try to restore and maintain
 the atrium's normal sinus rhythm
 with cardioversion (the application of
 an electrical shock to jolt an abnor-
 mal heartbeat into a normal one) and
 antiarrhythmic drugs.18 This method
 is known as "rhythm control." Alter-
 natively, physicians can try to control
 the response of the hearts ventrices
 to the atrial fibrillation by maintain-
 ing a good ventricular heart rate-a
 method known as "rate control."
 With this second strategy, physicians
 employ both drug and nonpharma-
 cologic therapies.19 In the AFFIRM
 study, patients were randomized to
 receive one of the two treatment
 strategies, and the patients received
 their care from their current physi-
 cian according to the study protocol's
 guidelines. Thus, while the patients
 were participating in a research trial,
 there was nothing experimental about
 their treatment. The only experimen-
 tal part of the trial was the fact that a
 patient's own treatment strategy was
 chosen randomly. (Results from AF-
 FIRM were published in December
 2002, and they suggested that rate
 control has important advantages
 over rhythm control as a therapeutic
 option.20)
 Now assume one change in the
 trial. In the actual study, cardiologists
 invited patients with atrial fibrillation
 to enter the AFFIRM trial. Patients
 who chose to enroll were assigned to
 one of the treatment strategies ran-
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 domly. If a patient declined enroll-
 ment, then the cardiologist provided
 one of the two treatment strategies ac-
 cording to the cardiologist's usual
 practice. But suppose instead that
 some cardiologists told their patients
 that they would treat the atrial fibril-
 lation only if the patients enrolled in
 the study. If a patient did not want to
 participate in AFFIRM, the cardiolo-
 gist would decline to accept the pa-
 tient for care or would end the pa-
 tient-physician relationship and in-
 struct the patient to obtain care from
 another cardiologist. Participation in
 AFFIRM would have been a condi-
 tion of receiving care from these car-
 diologists.
 Before discussing the propriety of
 such a condition, a couple of explana-
 tory points are in order. First, in the
 hypothetical trial, the informed con-
 sent process would remain generally
 unchanged. The patients would be
 given all of the information that nor-
 mally is given before enrolling in a
 clinical trial, and the patient would
 have the freedom to give or withhold
 consent. The one difference with cur-
 rent practice is that a decision not to
 enroll in the trial would entail the
 need to find another physician for
 care.
 Second, the point of using AF-
 FIRM as an example is to present a
 cinical trial in which patients are ran-
 domized between or among alterna-
 tive treatments, when (1) each of the
 therapies is well accepted for treating
 patients (that is, none of the alterna-
 tives is considered "experimental" or
 substandard therapy)21 and (2) data
 are lacking as to how the therapies
 compare in their ability to treat the
 patients' disease. As a corollary, there
 should be genuine uncertainty as to
 whether any of the treatments is supe-
 rior or inferior to the others (a condi-
 tion known as "dinical equipoise"22).
 Many trials would meet these criteria.
 For example, a study comparing two
 or more established drugs for arthritis
 might be conducted. Similarly, re-
 searchers might want to compare dif-
 ferent drugs used to lower cholesterol,
 reduce blood pressure, ameliorate de-
 pression, or limit the damage from a
 heart attack.
 The condition that none of the al-
 ternatives be "experimental" makes
 the proposal in this article more cau-
 tious than a new policy of the Centers
 for Medicare & Medicaid Services.
 That policy links Medicare coverage
 to patient participation in research
 trials. CMS designed the policy to
 systematically determine when
 Medicare should cover new and ex-
 pensive treatments or diagnostic tests.
 For example, coverage for new uses of
 approved anticancer drugs has been
 conditioned on the willingness of pa-
 tients to enroll in a cinical trial spon-
 sored by the National Cancer Insti-
 tute. But the CMS policy affects re-
 search on tests or treatments whose
 efficacy has not been established for
 the patients being studied.23
 Today's Research Guidelines
 T nder current practice, it is highly
 unlikely that approval would be
 given to a study in which physicians
 made participation in the study a
 condition for receiving treatment.
 Studies that involve testing or obser-
 vation of people must be authorized
 by an institutional review board
 (IRB), a committee that reviews the
 proposed study and considers
 whether it meets ethical standards for
 medical research. For example, an
 IRB would analyze the proposal to
 ensure that participation in the study
 is voluntary and that the health of the
 volun eers is not placed at too great a
 isk.24 For a study conditioning treat-
 ment on participation in research,
 IRBs would be concerned that poten-
 tial subjects would be coerced into
 enrolling in the trial-that a decision
 to e roll would not be truly volun-
 tary.
 Whether IRBs would be required
 to reject the hypothetical protocol is
 unce tain. According to the federal
 rules governing research on human
 subjects, the informed consent
 proc ss must include "a statement
 that participation is voluntary, [that]
 refusal to participate will involve no
 penalty or loss of benefits to which
 the subject is otherwise entitled, and
 [th t] the subject may discontinue
 parti ipation at any time without
 penal y or loss of benefits to which
 the subject is otherwise entitled."25
 One could argue that enrollment
 would satisfy the federal requirement
 of voluntary participation-a patient
 could enter the trial or seek care from
 another cardiologist. Moreover, the
 patients would not be deprived of any
 benefits to which they were "other-
 wise entitled"-after all, a patient is
 not entitled to obtain treatment from
 any particular cardiologist. Rather,
 the patient-physician relationship is a
 contractual one, based on the mutual
 consent of patient and physician.26
 Alternatively, one might concede
 that physicians have no duty to take
 on a particular patient-that they
 need not have a good reason for deny-
 ing care. However, physicians cannot
 deny care for bad reasons, and condi-
 tioning treatment on a willingness to
 participate in research might be con-
 sidered a bad reason, just as denying
 care because of a patient's race or sex
 constitutes a bad, and therefore unac-
 ceptable, reason. Moreover, if a pa-
 tient already was receiving care from a
 cardiologist, a refusal to continue
 treatment outside of the study would
 apparently constitute a penalty-a
 termination of care by the physician.
 Still, even if a cardiologist ended
 an existing patient-physician relation-
 ship, one could say that no violation
 of federal research rules had occurred.
 Since physicians can end a patient-
 physician relationship with proper
 notice,27 patients are not "otherwise
 entitled" to a particular physician's
 care.
 International standards for re-
 search are also ambiguous but give
 more reason to reject the hypothetical
 protocol. According to the World
 Medical Association's Declaration of
 Helsinki, "the refusal of a patient to
 participate in a study must never in-
 terfere with the patient-physician re-
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 lationship."28 It might be said that if
 physicians are not obligated to enter
 into particular patient-physician rela-
 tionships, then there is no "interfer-
 ence" when a physician decines to
 provide care. Yet withholding care if a
 patient refuses to enter a study ap-
 pears to constitute interference.
 The ethical guidelines of the
 Council for International Organiza-
 tions of Medical Sciences (CIOMS)
 also suggest that the hypothetical
 protocol would be unacceptable. In
 the commentary to the guideline on
 obtaining informed consent, the
 CIOMS guidelines state:
 Intimidation in any form invali-
 dates informed consent. Prospec-
 tive subjects who are patients often
 depend for medical care upon the
 physician/researcher, who conse-
 quently has a certain credibility in
 their eyes, and whose influence
 over them may be considerable,
 particularly if the study protocol
 has a therapeutic component.
 They may fear, for example, that
 refusal to participate would dam-
 age the therapeutic relationship or
 result in the withholding of health
 services. The physician/investigator
 must assure them that their deci-
 sion on whether to participate will
 not affect the therapeutic relation-
 ship or other benefits to which
 they are entitled ... .29
 On the one hand, the guidelines
 speak of maintaining "benefits to
 which [patients] are entitled," and
 patients are not entited to care from
 any particular cardiologist. On the
 other hand, the commentary explicit-
 ly discusses the concern that patients
 would enroll in a clinical trial to
 avoid having health services with-
 held.
 Whether or not the hypothetical
 version of AFFIRM would violate ex-
 isting standards for medical research,
 physicians and IRBs currently would
 be very reluctant to make enrollment
 in a research trial a condition for re-
 ceiving care. There would have to be
 a significant change in prevailing atti-
 tudes before the hypothetical version
 of AFFIRM could take place.
 To be sure, one can point to a
 common example in which IRBs al-
 ready permit researchers to link par-
 ticipation in a clinical trial to access
 to treatment: Many patients with
 cancer must agree to participate in a
 cinical trial as a condition of receiv-
 ing care. A patient may be referred to
 a specialized cancer center for treat-
 ment and find that treatment at the
 center would entail enrollment in a
 research study. Indeed, about 70 per-
 cent of children with cancer receive at
 least some of their treatment through
 a cinical trial sponsored by the Na-
 tional Cancer Institute,30 and in order
 to receive treatment at the National
 Institutes of Health Clinical Center,
 patients must agree to participate in
 medical research. An unwillingness to
 enroll would result in the patient re-
 turning for care to the patient's treat-
 ing physician. But the existence of
 this practice in oncology and other
 specialized areas does not change the
 fact that physicians typically would
 not decine to treat a patient outside
 of a research protocol if the patient
 refused to enroll in the physician's
 clinical trial.
 Making a Change
 N Ithough current practices dis-
 courage conditioning treatment
 on participation in research, physi-
 cians could make a strong case for
 having the freedom to treat patients
 only in the setting of a cinical trial,
 when a study is comparing well-es-
 tablished therapies.
 iElminating unnecessary imped-
 iments to medicalprogress. When a
 physician chooses between multiple
 therapies without knowing which
 therapy offers the greatest benefit, the
 physician may be subjecting many
 patients to inferior treatment. The
 physician could use the different al-
 ternatives equally to ensure that at
 least some patients receive the best
 treatment, or the physician could
 make a best guess as to the most ap-
 propriate treatment, knowing that ei-
 ther all or none of the patients will re-
 ceive the optimal therapy. (To be
 sure, with some conditions, one treat-
 ment might work best for some pa-
 tients, while another treatment might
 work best for others. But there will
 still be uncertainty as to which pa-
 tients do better with which treat-
 ments.)
 The only way to ensure that all pa-
 tients receive optimal therapy is to
 run a clinical trial comparing the al-
 ternatives. Moreover, the number
 who receive inferior treatment can be
 minimized by completing the trial
 rapidly. Physicians might therefore
 want to enroll all of their patients in a
 definitive study. If patients have the
 option of declining participation, the
 study could take much longer,31 as in
 the study of treatment for chronic
 lung disease for which recruitment
 took twice as long as expected.32
 Related to the interest in practic-
 ing medicine optimally is the interest
 in professional autonomy. Just as it is
 important for patients to have con-
 trol over the decision of whether to
 accept health care, it is important for
 physicians to have control over
 whom they treat and how they treat
 them. Thus, it is well recognized by
 the law that the patient-physician re-
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 lationship is created only with the
 voluntary consent of both patient
 and physician,33 and that physicians
 can choose the methods of surgery or
 the types of drugs they will employ.
 Note that the kinds of studies this
 article suggests have a kinship with
 the practices of hospitals at academic
 medical centers.34 Patients can choose
 care at a teaching hospital and accept
 the condition that medical students
 and residents will participate in their
 care, or they can decide to go else-
 where for their care and avoid treat-
 ment by students and residents. In
 other words, society already accepts
 the idea that patient participation in
 the achievement of an important so-
 cial goal can sometimes be made a
 condition of patient access to medical
 care.
 Encouraging more of a social
 sentiment in favor ofparticipation
 in medical research. Today's patients
 benefit greatly from the medical dis-
 coveries of yesterday, and those dis-
 coveries would not have occurred
 without the willingness of previous
 generations of patients to volunteer
 for clinical trials. In return for the
 benefits of earlier research, we might
 want to say that patients should be
 willing to participate in new trials. To
 put it another way, if people want to
 share in the benefits of their society,
 they arguably should share in its bur-
 dens, too. Moreover, we might say,
 no one is required to accept the bene-
 fits of medical treatment. Indeed, pa-
 tients enjoy a constitutional right to
 refuse medical treatment, even life-
 sustaining treatment. Whether to re-
 ceive medical treatment remains an
 option. As an option, its receipt
 could be made conditional on the
 willingness of the patient to partici-
 pate in medical research.
 On the other hand, it is question-
 able whether yesterday's research sub-
 jects can by their altruism bind
 today's patients to similar acts of al-
 truism.35 Participation in medical re-
 search is a morally praiseworthy act,
 but it is ordinarily not a morally re-
 quired act. The risks of experimental
 drugs or procedures can be substan-
 tial, and substantial risks ought to be
 assumed only voluntarily. If society
 were to condition medical treatment
 on enrollment in clinical trials, we
 would effectively create a moral duty
 to participate in research. A volun-
 tary, supererogatory act would be
 converted into an involuntary, oblig-
 atory act.
 To be sure, we often impose social
 obligations on the grounds that they
 benefit everyone. Speed limits con-
 strain my freedom when I drive, but
 they also ensure my safety.36 Insisting
 that patients become research sub-
 jects, however, may entail a different
 kind of sacrifice-that of one's health
 or life. And our society rejects the
 idea that people should have to com-
 promise their health for the sake of
 others.37 Accordingly, we should hesi-
 tate to conclude that patients must
 assume the risks of medical research
 for the benefit of other persons.
 This conclusion is reinforced by
 th  potential consequences of creat-
 ing duties to participate in medical
 research. If patients must become in-
 volved in medical research as a condi-
 tion of receiving medical treatment,
 then some sick people will simply
 forgo treatment.
 Although real duties to participate
 in medical research are problematic,
 the importance of medical research
 suggests that society can do more to
 encourage in people an inclination to
 participate in clinical trials. Encour-
 aging more of a sentiment in favor of
 participation would be particularly
 appropriate when (1) the risks to the
 individual are minimal and (2) there
 is an opportunity for patients to opt
 out of the clinical study. Patients
 should not have a duty to risk their
 health for others, and to the extent
 that they may feel that even a limited
 obligation has been created, it should
 be escapable.38 These qualifications
 would be satisfied in the kinds of
 studies that this article suggests. No
 patient would be subjected to a place-
 bo or an experimental therapy.
 Rather, all patients would be receiv-
 ing a well-accepted therapy, which to
 the best of our knowledge is as effec-
 tive as the alternatives. In addition,
 patients would be free to decine en-
 rollment in the study and seek care
 from a different physician. As long as
 the patient could indeed go some-
 where else for medical care, no oblig-
 ation to participate in research would
 exist.
 Answering the Objections
 ot only are there strong grounds
 for conditioning treatment on
 the willingness of patients to partici-
 pate in some clinical trials, but the
 usual justifications for strictly volun-
 tary participation are not present in
 the kinds of studies suggested by this
 article.
 Risk to patient welfare is not a
 concern. Most importantly, we do
 not have to worry about patients
 being forced to assume a risk to their
 health. In many clinical trials, a pa-
 tient may be randomized to either
 standard therapy or experimental
 therapy. In such cases, the experimen-
 tal therapy may not fulfill its promise
 and may have serious side effects. Pa-
 tients in the experimental therapy
 arm of the study would be harmed by
 their participation. Similarly, if an ex-
 perimental therapy is compared to
 placebo when established treatments
 already exist for the medical condi-
 tion being studied, patients in the
 placebo arm and possibly in the ex-
 perimental arm of the study will suf-
 fer by virtue of their participation in
 the cinical trial.39 In studies compar-
 ing well-accepted treatments, on the
 other hand, the patient would be re-
 ceiving the same care that would be
 provided in a visit to a physician's of-
 fice. In fact, the patient might receive
 better care by virtue of enrollment in
 the study; patients participating in re-
 search studies receive greater atten-
 tion to-and more rigorous observa-
 tion of-their medical conditions
 than do patients receiving care in
 their physicians' offices.40
 One might be concerned about
 denying patients the opportunity to
 weigh for themselves the advantages
 and disadvantages of the alternative
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 therapies and choose for themselves
 which treatment to receive. Even if
 there is no reason to think that one
 therapy is superior, individual pa-
 tients might find one therapy's side
 effects more distressing than those of
 the alternative therapies. But I do not
 believe that this concern, although it
 is legitimate, is decisive. Most pa-
 tients defer to their physician's recom-
 mendation rather than making their
 own choice. In addition, recall that
 patients who do not want to enter the
 trial are free to seek care from another
 physician and be treated as they pre-
 fer. Their freedom to choose would
 be restricted only if they chose to re-
 ceive treatment from a physician in-
 volved in the cinical trial.
 The possibility of coercion is not
 serious. Voluntary participation in
 medical research is important because
 patients may be reluctant to reject
 their physicians' invitation to enter a
 research study. A patient might undu-
 ly defer to the physician's judgment
 because of the physician's greater ex-
 pertise or because of fear that a refusal
 to participate might jeopardize the
 patient's relationship with the physi-
 cian. Patients might easily feel that
 they have no real choice when asked
 to enroll in a study.41 As a result, eth-
 ical guidelines for medical research
 include provisions to assure patients
 that they are free to choose not to
 participate.
 But with studies comparing differ-
 ent, well-accepted treatments, it
 would not be troublesome if patients
 felt some pressure to enroll. If they
 agreed to participate, they would not
 be placed at any greater risk of harm
 than if they did not. Moreover, the
 purpose of the pressure is to encour-
 age them to help society understand
 and treat disease. There is nothing
 wrong with reasonable efforts at per-
 suasion when the persuasion is de-
 signed to foster socially desirable be-
 havior.
 In addition, studies comparing
 well-established treatments lack the
 worrisome elements present in situa-
 tions that are condemned as coercive.
 For example, people who choose to
 enroll in the study would not be dri-
 ven by desperation or by the lack of a
 good alternative,42 nor would they
 have succumbed to threats of physical
 harm.43
 More precisely, when a physician
 conditions treatment on a patient's
 enrollment in a study comparing
 well-established treatments, the
 physician is not presenting the pa-
 tient with a threat. As Alan
 Wertheimer observes, A threatens B
 when the consequence of B's declin-
 ing A's proposal is that B will be worse
 off than B would otherwise be.44
 However, the patient who declines to
 enroll in the study comparing well-es-
 tablished therapies will not be worse
 off for having refused. The patient
 will receive treatment with one of the
 therapies being studied, just as would
 have happened if the physician had
 not invited the patient to enroll in the
 study.
 To be sure, the patient who must
 find another physician after declining
 enrollment may be worse off when
 compared with the alternative of de-
 dining enrollment and still remaining
 with the physician. But that is not the
 relevant moral comparison. The issue
 is whether the patient is deprived of
 some interest to which the patient
 would otherwise be entided. Whether
 the patient is worse off depends on
 whether the first physician has an un-
 derlying obligation to care for the pa-
 tient,45 and this takes us back to the
 earlier point that patients are not en-
 titled to receive care from a particular
 physician.
 In other words, there is a circulari-
 ty to the argument against the hypo-
 thetical version of AFFIRM. Condi-
 tioning treatment on participation in
 the study is said to be unacceptably
 coercive because the patient would be
 threatened with the loss of the physi-
 cian. But the patient ordinarily lacks
 any entitlement to a particular pa-
 tient-physician relationship. She
 would have such an entitlement only
 if care is denied for a bad reason. In
 identifying what would constitute a
 bad reason, we must find something
 that goes beyond the mere denial of
 care-racial bias or exposure to a sig-
 nificant health risk, for example. If
 the bad reason is simply the denial of
 care, then the argument becomes cir-
 cular.
 By analogy, physicians also do not
 unduly coerce their patients by rais-
 ing their fees. The physician effective-
 ly tells patients that access to further
 care will be denied unless the patient
 agrees to pay more for the care, and
 patie ts may be worse off for having
 to change physicians if they cannot
 afford the fee increase. Nevertheless,
 because the patient is not entitled to
 care indefinitely at a fixed fee, a rea-
 sonable fee increase would not be
 considered unethical coercion.
 That the hypothetical study in-
 volves a noncoercive offer rather than
 a coercive threat can be seen from an-
 other perspective-what the patient
 would have to give up by enrolling in
 the study. Consider in this regard
 what the physician might say to a pa-
 tient:
 When I first started treating your
 chronic atrial fibrillation, I men-
 tioned two strategies for treatment,
 rhythm control and rate control.
 Many cardiologists and I prefer
 HASTINGS CENTER REPORT 25
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 rhythm control, but others prefer
 rate control. As I also mentioned,
 data are lacking as to which strate-
 gy works better. There now is a
 study comparing the two strate-
 gies, and I believe it important
 that the study be completed so
 that we can find out if one of the
 two strategies works better.
 Accordingly, I will continue treat-
 ing your atrial fibrillation if you
 enroll in the study. If you do, then
 whether you remain on rhythm
 control or whether I treat you with
 rate control instead will be decided
 randomly. While you are in the
 study, the costs of your atrial fibril-
 lation treatment will be paid by
 the study sponsor. If you do not
 want to enroll in the study, I will
 refer you to another cardiologist
 who can continue with the
 rhythm control strategy, and as
 now, your insurer and you will be
 responsible for the costs of your
 care.
 By going into the study, all the pa-
 tients would have to forgo would be
 their ability to choose between two
 treatment strategies when no one re-
 ally knows which strategy is more de-
 sirable. And in return for forgoing
 this choice, the patients might be re-
 lieved of their financial obligations
 for the costs of care.46
 Moreover, if physicians were to
 condition treatment on participation
 in research, they might be less likely
 to encourage participation in a biased
 way. If a physician can only recom-
 mend that a patient volunteer for re-
 search, the physician may be more
 aggressive with some patients and less
 aggressive with others in encouraging
 participation. Physicians might put
 more pressure on their more vulnera-
 ble and less powerful patients, who
 are less likely to reject their physi-
 cian's offers. But if the physician links
 treatment with research participation,
 then every patient faces the same
 pressure to enroll in the research trial.
 In other words, allowing the physi-
 ticipation in research may simply
 have the effect of changing the demo-
 graphics of the research subjects to
 include a more diverse patient popu-
 lation.47 (The fact that conditioning
 treatment on participation may result
 in a more diverse population of re-
 search subjects provides another im-
 portant reason for preferring this ap-
 proach over other ways to promote
 participation, such as television or
 radio advertising.48)
 Note, too, that this article's pro-
 posal is less coercive to patients than
 an alternative proposal, offered by
 Robert Truog and colleagues, that
 would entail waiving informed con-
 sent for trials that compare estab-
 lished therapies.49 Under that propos-
 al, patients would be told about the
 institution's policy of conducting
 comparative clinical trials without the
 usual process of informed consent,
 but the patients would not be asked
for consent before their actual enroll-
 ment into a comparative trial. As a
 condition of receiving care at the in-
 stitution, patients would lose their
 ability to choose whether to partici-
 pate in the institutions comparative
 trials.
 Threat to patient trust. We
 might be concerned that condition-
 ing treatment on participating in re-
 search would undermine patient trust
 in the medical profession. If patients
 felt coerced by their physicians' re-
 s arch requirements, they would be
 inclined to wonder whether their
 physicians were compromising their
 interests for the benefit of other inter-
 ests.
 W  should be wary of measures
 that might undermine patient trust.
 Because patients lack medical exper-
 tise and because the patient's health
 and even life may hang in the bal-
 ance, patients are highly dependent
 on their physicians. With so much at
 stake for the patient and so much
 power in the hands of the physician,
 patie ts will not be willing to rely on
 their physicians' judgment unless
 they can trust that physicians use
 their skills and power on their pa-
 Concerns about patient trust are
 especially important in medical re-
 search. Medical research generally in-
v lves patients accepting some risks
 to their own health for the benefit of
fut re patients. Because medical re-
 search is predicated on a sacrifice of
 patient welfare, it is important to as-
 sure patients that the risk will be
 inimized. Moreover, past abuses of
 patient welfare in research give pa-
 tients grounds for skepticism about
 the trustworthiness of today's re-
 searcher. The Tuskegee syphilis
 stud 50 and the radiation studies of
 cancer patients51 are two of the more
 notable examples of abuse.
 While these concerns about trust
 are important, they should not lead
 us to reject entirely the possibility of
 onditioning treatment on participa-
 tion in research. Past abuses in med-
 ical research involved two problemat-
 ic el ments, neither of which is pre-
 sent in the kind of trial suggested by
 this rticle. First, many abusive stud-
 ies volved the deception of the re-
 search subjects. They were not given
 accurate information about the trials
 in which they were participating. As
 previously indicated, the ability to
 condition treatment on research par-
 ticipation would not entail any other
 changes in the requirements of in-
 formed consent. Second, many of the
 abusive trials placed patients at an
 unacceptable risk to their health. In
 contrast, the kinds of studies that sat-
 isfy this artice's proposal are those in
 which patients would receive one of
 two or more well-accepted thera-
 pies-therapies that they would re-
 ceive from any number of doctors
 whom they might see for care.
 Moreover, conducting research
 at compares established therapies in
 order to discover whether one is bet-
 ter may well bolster patient trust. Pa-
 tients ought to be reassured by know-
 ing that their physicians are trying to
 find out which treatments are opti-
 mal. In fact, research on patient re-
 luctance to enroll in research trials in-
 dicates that key considerations in the
 patient's decision are the physician's
 cian to condition treatment on par- tients' behalf.  enthusiasm for the study and whether
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 the physician is truly uncertain about
 the value of the different therapies.52
 Accordingly, conditioning treatment
 on the patient's willingness to enter
 the trial can directly respond to pa-
 tient concerns to the extent that the
 physician expresses enthusiasm for
 the study and acknowledges uncer-
 tainty about how the treatments
 compare.
 Too Lax or Too Strict
 /Many people have been unneces-
 sarily harmed by research that
 did not adhere to sufficiently strict
 ethical safeguards. Steps should be
 taken to protect against future harm.
 At the same time, ethical safeguards
 can become too strict. Sometimes,
 important advances in medical un-
 derstanding are slowed or stymied by
 unnecessary limits on the ability of
 physicians to encourage their patients
 to participate in cinical trials. When
 a cinical trial compares two or more
 well-established therapies to deter-
 mine which is better, physicians
 ought to be able to condition treat-
 ment on a patient's willingness to en-
 roll in the trial.
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